AN2 Therapeutics $69 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the upsized initial public offering of 4,600,000 shares of common stock of AN2 Therapeutics, Inc. at $15.00 per share, for total gross proceeds of $69 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “ANTX.”
Based in Menlo Park, California, AN2 Therapeutics is a clinical-stage biotechnology company developing treatments for rare, chronic and serious infectious diseases with high unmet needs. Their initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial (NTM) lung disease.
The Davis Polk corporate team included partner Emily Roberts and associates Jonathan Bye and Bex Childress. The intellectual property and technology transactions team included counsel Bonnie Chen and associates David A. Frey and Alison T. Chin. The tax team included partner Ethan R. Goldman and associate Dylan J. Steiner. Counsel Marcie A. Goldstein provided FINRA advice. Counsel Sarah E. Kim provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.